A blood-flow glucose consumption mismatch that predicted pancreatic tumor aggressiveness has been identified by researchers from Turku, Finland. These are the results of a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Based on these findings, they suggested that the relationship between several physiological tumor parameters might provide more important information about a tumor than just looking at any of these parameters alone.
Gaber Komar, M.D., research fellow at the Turku PET Center, and colleagues investigated the importance of two physiological parameters in the tumor microenvironment among patients with pancreatic tumors to evaluate tumor aggressiveness. The parameters measured were blood flow in the tumor tissue and glucose consumption, which could be seen as a measurement of general metabolic activity of a tissue.
"Imaging of several of these tumor parameters might be important for the planning and success of oncologic therapies," Komar said. "We believe that a better understanding of these mechanisms may help overcome the general treatment resistance of pancreatic cancer."